Drug Pipeline

YL201 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
1
Recruiting
2
Phase 3
2
Top Sponsors
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-21 NCT06898957
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death…
Enrollment reduced: 200 -> 29 participants
Active Studies by Phase
Phase 3
2
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07487896 A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With… Advanced Esophageal Squamous Cell Carcinoma Not Yet Recruiting
NCT06612151 A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer Small Cell Lung Cancer Active, Not Recruiting
Phase 1/2
NCT07407933 A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With… Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma Recruiting
Phase 1
NCT06898957 Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death… Small Cell Lung Cancer Active, Not Recruiting
Sponsors Running YL201 Trials
Disease Areas
Get alerts when YL201 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free